EPIGRAL

Epigral Share Price

₹1,813.75 +21.15 (1.18%)

17 Mar, 2025 00:34

SIP TrendupStart SIP in EPIGRAL

Start SIP

Performance

  • Low
  • ₹1,769
  • High
  • ₹1,828
  • 52 Week Low
  • ₹950
  • 52 Week High
  • ₹2,407
  • Open Price₹1,810
  • Previous Close₹1,793
  • Volume21,647

Investment Returns

  • Over 1 Month + 3.61%
  • Over 3 Month -13.06%
  • Over 6 Month -11.42%
  • Over 1 Year + 82.29%
SIP Lightning

Smart Investing Starts Here Start SIP with Epigral for Steady Growth!

Invest Now

Epigral Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 7,825
  • P/B Ratio
  • 5.6
  • Average True Range
  • 96.02
  • EPS
  • 80.68
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -18.41
  • RSI
  • 53.15
  • MFI
  • 47.78

Epigral Financials

Epigral Technicals

EMA & SMA

Current Price
₹1,813.75
+ 21.15 (1.18%)
pointer
  • stock-down_img
  • Bearish Moving Average 4
  • stock-up_img
  • Bullish Moving Average 12
  • 20 Day
  • ₹1,765.17
  • 50 Day
  • ₹1,800.90
  • 100 Day
  • ₹1,835.73
  • 200 Day
  • ₹1,760.64

Resistance and Support

1803.37 Pivot Speed
  • R3 1,896.53
  • R2 1,862.02
  • R1 1,837.88
  • S1 1,779.23
  • S2 1,744.72
  • S3 1,720.58

What's your outlook on Epigral?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

EpigraL Ltd. is a prominent manufacturer of high-performance specialty chemicals and coatings in India. The company specializes in producing epoxy resins, adhesives, and surface treatment products, catering to various industries including automotive, construction, and electronics.

Epigral Ltd has an operating revenue of Rs. 2,447.13 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of 15% is great, ROE of 15% is good. The company has a reasonable debt to equity of 39%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 2% and -0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 57 indicates it belongs to a fair industry group of Chemicals-Specialty and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Epigral Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-27 Quarterly Results & Interim Dividend
2024-11-09 Quarterly Results
2024-08-14 To consider Fund Raising
2024-07-24 Quarterly Results
2024-04-22 Audited Results & Final Dividend
Date Purpose Remarks
2025-02-07 INTERIM Rs.2.50 per share(25%)Interim Dividend
2024-07-02 FINAL Rs.5.00 per share(50%)Final Dividend
2023-06-20 FINAL Rs.2.50 per share(25%)Final Dividend
2023-02-01 INTERIM Rs.2.50 per share(25%)Interim Dividend
View More

Epigral F&O

Epigral Shareholding Pattern

68.94%
4.15%
3.01%
17.37%
6.53%

About Epigral

  • NSE Symbol
  • EPIGRAL
  • BSE Symbol
  • 543332
  • Chairman & Managing Director
  • Mr. Maulik Jayantibhai Patel
  • ISIN
  • INE071N01016

Similar Stocks to Epigral

Epigral FAQs

Epigral share price is ₹1,813 As on 17 March, 2025 | 00:20

The Market Cap of Epigral is ₹7824.8 Cr As on 17 March, 2025 | 00:20

The P/E ratio of Epigral is 22.5 As on 17 March, 2025 | 00:20

The PB ratio of Epigral is 5.6 As on 17 March, 2025 | 00:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23